Collaboration with the NIH Nanoparticle Characterization Lab

In April 2018, the NIH/NCI Nanoparticle Characterization Laboratory (NCL) accepted our propofol-loaded polymeric perfluorocarbon nanoemulsions into their characterization and testing program, which is designed to promote the clinical translation of novel nanomedicines. These propofol-loaded nanoparticles  will now undergo their rigorous in vitro and in vivo evaluation. If these particles pass the NCL assays with acceptable results, we plan to apply for an investigatory license from the FDA for first-in-human trials to complete noninvasive functional brain mapping as part of neurologic and neurosurgical evaluations.

https://nanolab.cancer.gov/sites/default/files/May%202018.pdf